Clicky

Cullinan Management, Inc.(CGEM) News

Date Title
May 29 Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference
May 22 Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025
Apr 23 Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, at ASCO 2025
May 15 Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
May 9 Insider Sale at Cullinan Therapeutics Inc (CGEM): Chief Scientific Officer Jennifer Michaelson ...
Apr 29 Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer
Apr 24 Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday?
Apr 24 Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024
Apr 16 Cullinan Shifts Focus From Oncology To Autoimmune Disorders, Raises $280M Via Equity
Apr 16 Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases
Apr 16 Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement
Apr 16 Cullinan changes name, pivots to autoimmune disease
Mar 16 Cullinan Oncology Inc (CGEM) Reports Fourth Quarter and Full Year 2023 Financial Results
Mar 15 Here's Why We're Not Too Worried About Cullinan Oncology's (NASDAQ:CGEM) Cash Burn Situation
Mar 14 Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Mar 1 Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma
Feb 27 Cullinan Oncology to Participate in Upcoming Investor Conferences
Dec 18 Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Dec 14 Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines
Nov 8 Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results